Abstract: Background: Bone marrow-derived mesenchymal stem cells (BM-MSCs) play an important role in cancer development and progression. However, the mechanism by which they enhance the chemoresistance of ovarian cancer is unknown. Methods: Conditioned media of BM-MSCs (BM-MSC-CM) were analyzed using a technique based on microRNA arrays. The most highly expressed microRNAs were selected for testing their effects on glycolysis and chemoresistance in SKOV3 and COC1 ovarian cancer cells. The targeted gene and related signaling pathway were investigated using in silico analysis and in vitro cancer cell models. Kaplan-Merier survival analysis was performed on a population of 59 patients enrolled to analyze the clinical significance of microRNA findings in the prognosis of ovarian cancer. Results: MiR-1180 was the most abundant microRNA detected in BM-MSC-CM, which simultaneously induces glycolysis and chemoresistance (against cisplatin) in ovarian cancer cells. The secreted frizzled-related protein 1 (SFRP1) gene was identified as a major target of miR-1180. The overexpression of miR-1180 led to the activation of Wnt signaling and its downstream components, namely Wnt5a, β-catenin, c-Myc, and CyclinD1, which are responsible for glycolysis-induced chemoresistance. The miR-1180 level was inversely correlated with SFRP1 mRNA expression in ovarian cancer tissue. The overexpressed miR-1180 was associated with a poor prognosis for the long-term (96-month) survival of ovarian cancer patients. Conclusions: BM-MSCs enhance the chemoresistance of ovarian cancer by releasing miR-1180. The released miR-1180 activates the Wnt signaling pathway in cancer cells by targeting SFRP1. The enhanced Wnt signaling upregulates the glycolytic level (i.e. Warburg effect), which reinforces the chemoresistance property of ovarian cancer cells.

骨髓间充质干细胞释放miR-1180上调Wnt信号通路活性并促进卵巢癌细胞糖酵解和化疗耐药能力的研究

[1]Abubaker K, Latifi A, Luwor R, et al., 2013. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer, 12:24.

[2]Arend RC, Londoño-Joshi AI, Straughn JM Jr, et al., 2013. The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol, 131(3):772-779.

[3]Barbolina MV, Burkhalter RJ, Stack MS, 2011. Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J, 437(1):1-12.

[4]Benabbou N, Mirshahi P, Bordu C, et al., 2014. A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line. Int J Oncol, 45(4):1372-1380.

[5]Burkhalter RJ, Symowicz J, Hudson LG, et al., 2011. Integrin regulation of β-catenin signaling in ovarian carcinoma. J Biol Chem, 286(26):23467-23475.

[6]Cai JY, Wang JC, Huang YN, et al., 2016. ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells. Cell Death Dis, 7(11):e2459.

[7]Castells M, Milhas D, Gandy C, et al., 2013. Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell Death Dis, 4(10):e887.

[8]Chen EG, Zhang JS, Xu S, et al., 2017. Long non-coding RNA DGCR5 is involved in the regulation of proliferation, migration and invasion of lung cancer by targeting miR-1180. Am J Cancer Res, 7(7):1463-1475.

[9]Coffman LG, Choi YJ, McLean K, et al., 2016. Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget, 7(6):6916-6932.

[10]https://doi.org/10.18632/oncotarget.6870

[11]Das B, Kashino SS, Pulu I, et al., 2013. CD271⁺ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med, 5(170):170ra13.

[12]Fu DL, Jiang QH, He FM, et al., 2017. Adhesion of bone marrow mesenchymal stem cells on porous titanium surfaces with strontium-doped hydroxyapatite coating. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(9):778-788.

[13]Ganapathy-Kanniappan S, Geschwind JF, 2013. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer, 12:152.

[14]Ge QQ, Wang CH, Chen Z, et al., 2017. The suppressive effects of miR-1180-5p on the proliferation and tumorigenicity of bladder cancer cells. Histol Histopathol, 32(1):77-86.

[15]https://doi.org/10.14670/HH-11-772

[16]Gu L, Zhang JQ, Shi MM, et al., 2017. The effects of miRNA-1180 on suppression of pancreatic cancer. Am J Transl Res, 9(6):2798-2806.

[17]He YF, Zhu QJ, Chen M, et al., 2016. The changing 50% inhibitory concentration (IC₅₀) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. Oncotarget, 7(43):70803-70821.

[18]https://doi.org/10.18632/oncotarget.12223

[19]Huang RX, Wu D, Yuan Y, et al., 2014. CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients. PLoS ONE, 9(11):e112209.

[20]Icard P, Shulman S, Farhat D, et al., 2018. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat, 38:1-11.

[21]Jones EA, Crawford A, English A, et al., 2008. Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level. Arthritis Rheum, 58(6):1731-1740.

[22]Latifi A, Abubaker K, Castrechini N, et al., 2011. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem, 112(10):2850-2864.

[23]Lis R, Touboul C, Mirshahi P, et al., 2011. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int J Cancer, 128(3):715-725.

[24]Lis R, Touboul C, Halabi NM, et al., 2014. Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile. J Transl Med, 12:59.

[25]Mader EK, Maeyama Y, Lin Y, et al., 2009. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res, 15(23):7246-7255.

[26]McLean K, Gong YS, Choi Y, et al., 2011. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest, 121(8):3206-3219.

[27]Munoz JL, Rodriguez-Cruz V, Walker ND, et al., 2015. Temozolomide resistance and tumor recurrence: halting the Hedgehog. Cancer Cell Microenviron, 2(2):e747.

[28]Noort WA, Oerlemans MIFJ, Rozemuller H, et al., 2012. Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation. J Cell Mol Med, 16(8):1827-1839.

[29]Pate KT, Stringari C, Sprowl-Tanio S, et al., 2014. Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J, 33(13):1454-1473.

[30]https://doi.org/10.15252/embj.201488598

[31]Quirici N, Soligo D, Bossolasco P, et al., 2002. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol, 30(7):783-791.

[32]Rasini V, Dominici M, Kluba T, et al., 2013. Mesenchymal stromal/stem cells markers in the human bone marrow. Cytotherapy, 15(3):292-306.

[33]Ridge SM, Sullivan FJ, Glynn SA, 2017. Mesenchymal stem cells: key players in cancer progression. Mol Cancer, 16:31.

[34]Suh DH, Kim HS, Kim B, et al., 2014. Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication. Biochem Pharmacol, 92(1):43-54.

[35]Takahashi-Yanaga F, Kahn M, 2010. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res, 16(12):3153-3162.

[36]Tan GS, Wu LW, Tan JF, et al., 2016. MiR-1180 promotes apoptotic resistance to human hepatocellular carcinoma via activation of NF-κB signaling pathway. Sci Rep, 6: 22328.

[37]Touboul C, Lis R, al Farsi H, et al., 2013. Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model. J Transl Med, 11:28.

[38]Touboul C, Vidal F, Pasquier J, et al., 2014. Role of mesenchymal cells in the natural history of ovarian cancer: a review. J Transl Med, 12:271.

[39]Tyciakova S, Matuskova M, Bohovic R, et al., 2015. Genetically engineered mesenchymal stromal cells producing TNFα have tumour suppressing effect on human melanoma xenograft. J Gene Med, 17(1-2):54-67.

[40]Vallabhaneni KC, Hassler MY, Abraham A, et al., 2016. Mesenchymal stem/stromal cells under stress increase osteosarcoma migration and apoptosis resistance via extracellular vesicle mediated communication. PLoS ONE, 11(11):e0166027.

[41]Wang CH, Chen Z, Ge QQ, et al., 2014. Up-regulation of p21^WAF1/CIP1 by miRNAs and its implications in bladder cancer cells. FEBS Lett, 588(24):4654-4664.

[42]Wang WW, Zhong W, Yuan JH, et al., 2015. Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma. Oncotarget, 6(39):42276-42289.

[43]https://doi.org/10.18632/oncotarget.5514

[44]Warburg O, 1956. On the origin of cancer cells. Science, 123(3191):309-314.

[45]Watson JT, Foo T, Wu J, et al., 2013. CD271 as a marker for mesenchymal stem cells in bone marrow versus umbilical cord blood. Cells Tissues Organs, 197(6):496-504.

[46]Watts TL, Cui RW, Szaniszlo P, et al., 2016. PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment. J Transl Med, 14(1):337.

[47]Wu H, Ding ZH, Hu DQ, et al., 2012. Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. J Pathol, 227(2):189-199.

[48]Wu M, Neilson A, Swift AL, et al., 2007. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol, 292(1):C125-C136.

[49]Xiang BY, Chen L, Wang XJ, et al., 2017. Mesenchymal stem cells as therapeutic agents and in gene delivery for the treatment of glioma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 18(9):737-746.

[50]Yang YY, Otte A, Hass R, 2015. Human mesenchymal stroma/ stem cells exchange membrane proteins and alter functionality during interaction with different tumor cell lines. Stem Cells Dev, 24(10):1205-1222.

[51]Yao K, Fu XF, Du X, et al., 2018. PGC-1α coordinates with Bcl-2 to control the cell cycle in U251 cells through reducing ROS. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(6):415-424.

[52]Yao ZY, Chen WB, Shao SS, et al., 2018. Role of exosome-associated microRNA in diagnostic and therapeutic applications to metabolic disorders. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(3):183-198.

[53]Zhang MY, He YF, Sun XJ, et al., 2014. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res, 7:19.

[54]Zhou X, Zhu HQ, Ma CQ, et al., 2016. MiR-1180 promoted the proliferation of hepatocellular carcinoma cells by repressing TNIP2 expression. Biomed Pharmacother, 79: 315-320.

[55]Zhu DY, Gao WX, Zhang ZM, 2018. MicroRNA-1180 is associated with growth and apoptosis in prostate cancer via TNF receptor associated factor 1 expression regulation and nuclear factor-κB signaling pathway activation. Oncol Lett, 15(4):4775-4780.